Lowering blood sugar below normal levels is hardly unique to semaglutide or GLP1s in general. Most drugs targetting type 2 diabetes can do so and sometimes need to be adjusted to prevent hypoglycemic events. Insulin in particular poses a significant risk of hypoglycemic events which is why many insurances cover continuous glucose monitors for those taking insulin.